SPOTLIGHT -
New products of interest to our readers
FDA extends approval of Evkeeza for homozygous familial hypercholesterolemia in young children
Evkeeza is the first angiopoietin-like 3 (ANGPTL3) inhibitor indicated for patients as young at 5 years to control high levels of low-density lipoprotein cholesterol (LDL-C) as a result of HoFH.
Food Insecurity and the Dangers of Infant Formula Dilution
Improving built environments could help address adolescent obesity
Built environments, but not social and economic environments, were negatively associated with BMI and overweight or obesity status, with a stronger association among adolescents with longer exposure to their built environment.
Demystifying Infant Formula
Guidelines for PUZZLER, Contemporary Pediatrics
Early return to school linked to faster recovery, less symptom burden for concussed children
A study found that children with acute concussions could have less symptom burden with an earlier return to school.
